Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity.

Hepatotoxicity of coumarin is attributed to metabolic activation to an epoxide intermediate, coumarin 3,4-epoxide (CE). However, whereas rats are most susceptible to coumarin-induced hepatotoxicity, formation of CE is greatest in mouse liver microsomes, a species showing little evidence of hepatotoxicity. Therefore, the present work was designed to test the hypothesis that detoxification of CE is a major determinant of coumarin hepatotoxicity. CE can either rearrange spontaneously to o-hydroxyphenylacetaldehyde (o-HPA) or be conjugated with gluatathione (GSH). o-HPA is hepatotoxic and is further detoxified by oxidation to o-hydroxyphenylacetic acid (o-HPAA). In vitro experiments were conducted using mouse liver microsomes to generate a constant amount of CE, and cytosols from F344 rats, B6C3F1 mice, and human liver were used to characterize CE detoxification. All metabolites were quantified by HPLC methods with UV detection. In rats and mice, GSH conjugation occurred non-enzymatically and through glutathione-S-transferases (GSTs), and the kinetics of GSH conjugation were similar in rats and mice. In rat liver cytosol, oxidation of o-HPA to o-HPAA was characterized with a high affinity K(m) of approximately 12 microM, and a V(max) of approximately 1.5 nmol/min/mg protein. In contrast, the K(m) and V(max) for o-HPA oxidation in mouse liver cytosol were approximately 1.7 microM and 5 nmol/min/mg protein, respectively, yielding a total intrinsic clearance through oxidation to o-HPAA that was 20 times higher in mouse than in rats. Human cytosols (two separate pools) detoxified CE through o-HPA oxidation with an apparent K(m) of 0.84 microM and a V(max) of 5.7 nmol/min/mg protein, for a net intrinsic clearance that was more than 50 times higher than the rat. All species also reduced o-HPA to o-hydroxyphenylethanol (o-HPE), but this was only a major reaction in rats. In the presence of a metabolic reaction replete with all necessary cofactors, GSH conjugation accounted for nearly half of all CE metabolites in rat and mouse, whereas the GSH conjugate represented only 10% of the metabolites in human cytosol. In mouse, o-HPAA represented the major ring-opened metabolite, accounting for the remaining 50% of metabolites, and in human cytosol, o-HPAA was the major metabolite, representing nearly 90% of all CE metabolites. In contrast, no o-HPAA was detected in rats, whereas o-HPE represented a major metabolite. Collectively, these in vitro data implicate o-HPA detoxification through oxidation to o-HPAA as the major determinant of species differences in coumarin-induced hepatotoxicity.

[1]  D. Lewis,et al.  Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites. , 1989, Toxicology and Applied Pharmacology.

[2]  M. Lang,et al.  Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. , 1988, Biochemical pharmacology.

[3]  O Pelkonen,et al.  Polymorphisms of CYP2A6 and its practical consequences. , 2001, British journal of clinical pharmacology.

[4]  D. Lewis,et al.  Comparison of the hepatic effects of coumarin, 3,4-dimethylcoumarin, dihydrocoumarin and 6-methylcoumarin in the rat. , 1994, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[5]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[6]  B. Lake Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat. , 1984, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

[7]  A. M. Api,et al.  Comparative metabolism and kinetics of coumarin in mice and rats. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[8]  S. Born,et al.  o-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[9]  G. Bepler,et al.  Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. , 2001, Toxicology.

[10]  J. Idle,et al.  Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. , 1992, Journal of chromatography.

[11]  A. Yoshida,et al.  Determination of genotypes of human aldehyde dehydrogenase ALDH2 locus. , 1983, American journal of human genetics.

[12]  R. Lindberg,et al.  Mouse steroid 15 alpha-hydroxylase gene family: identification of type II P-450(15)alpha as coumarin 7-hydroxylase. , 1989, Biochemistry.

[13]  A. Parkinson,et al.  Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. , 1992, Archives of biochemistry and biophysics.

[14]  V. Vasiliou,et al.  Aldehyde dehydrogenase gene superfamily: the 2002 update. , 2003, Chemico-biological interactions.

[15]  J. Mohler,et al.  An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin , 2005, Journal of Cancer Research and Clinical Oncology.

[16]  D. Agarwal,et al.  Liver alcohol dehydrogenase and aldehyde dehydrogenase in the Japanese: isozyme variation and its possible role in alcohol intoxication. , 1980, American journal of human genetics.

[17]  S. Born,et al.  Synthesis and reactivity of coumarin 3,4-epoxide. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[18]  J. Idle,et al.  A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[19]  M. Przybylski,et al.  Coumarin mercapturic acid isolated from rat urine indicates metabolic formation of coumarin 3,4-epoxide. , 1991, Chemical research in toxicology.

[20]  B. Lake,et al.  Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[21]  J. Stengård,et al.  Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C‐oxidase , 1998, FEBS letters.

[22]  M. Ingelman-Sundberg,et al.  Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.

[23]  J. Lipsky,et al.  Inhibition of recombinant human mitochondrial and cytosolic aldehyde dehydrogenases by two candidates for the active metabolites of disulfiram. , 1997, Biochemistry.

[24]  H. Yamazaki,et al.  Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  D. Egan,et al.  The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. , 1990, Drug metabolism reviews.

[26]  A. Cohen Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. , 1979, Food and cosmetics toxicology.

[27]  M. Oscarson Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[28]  R. T. Williams,et al.  The Metabolism of [3-14C]Coumarin , 1961 .

[29]  S. Born,et al.  Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[30]  V. Vasiliou,et al.  Polymorphisms of Human Aldehyde Dehydrogenases , 2000, Pharmacology.

[31]  J. Idle,et al.  Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 , 1998, European Journal of Clinical Pharmacology.

[32]  D. Agarwal,et al.  Aldehyde Dehydrogenase Deficiency as Cause of Facial Flushing Reaction to Alcohol in Japanese , 1995, Alcohol health and research world.

[33]  R. C. Longland,et al.  Metabolism of Coumarin in Man , 1969, Nature.

[34]  A. Hiratsuka,et al.  4-Hydroxy-2(E)-nonenal enantiomers: (S)-selective inactivation of glyceraldehyde-3-phosphate dehydrogenase and detoxification by rat glutathione S-transferase A4-4. , 2000, The Biochemical journal.

[35]  L. Hazleton,et al.  Toxicity of coumarin. , 1956, The Journal of pharmacology and experimental therapeutics.

[36]  B. Green,et al.  Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. , 1999, Pharmacogenetics.

[37]  J. Fry,et al.  Species differences in the metabolism and hepatotoxicity of coumarin. , 1993, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[38]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[39]  W B Jakoby,et al.  Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. , 1974, The Journal of biological chemistry.

[40]  O Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.

[41]  H. Ramsdell,et al.  Mouse liver glutathione S-transferase isoenzyme activity toward aflatoxin B1-8,9-epoxide and benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide. , 1990, Toxicology and applied pharmacology.

[42]  D. G. Walters,et al.  Identification of o-hydroxyphenylacetaldehyde as a major metabolite of coumarin in rat hepatic microsomes. , 1992, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[43]  J. Freudenstein,et al.  Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. , 2003, International journal of clinical pharmacology and therapeutics.

[44]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[45]  J. Fry,et al.  O-hydroxyphenylacetaldehyde: a major novel metabolite of coumarin formed by rat, gerbil and human liver microsomes. , 1991, Biochemical and biophysical research communications.

[46]  S. Born,et al.  In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  M. Lang,et al.  Cytochrome P4502A-mediated coumarin 7-hydroxylation and testosterone hydroxylation in mouse and rat lung. , 1993, Pharmacology & toxicology.

[48]  B. Lake,et al.  Comparison of the hepatotoxicity of coumarin in the rat, mouse, and Syrian hamster: a dose and time response study. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[49]  D. Judah,et al.  Metabolic basis of the species difference to aflatoxin B1 induced hepatotoxicity. , 1983, Biochemical and biophysical research communications.

[50]  D. G. Walters,et al.  Metabolism of coumarin and 7-ethoxycoumarin by rat, mouse, guinea pig, cynomolgus monkey and human precision-cut liver slices. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[51]  O. Pelkonen,et al.  CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.

[52]  G. Daston,et al.  Liquid chromatographic determination of the glutathione conjugate and ring-opened metabolites formed from coumarin epoxidation. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.